News
A New Treatment Option for NET Patients
The U.S. Food and Drug Administration (FDA) has approved cabozantinib for the treatment of previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors
Early Positive Signs in CAR T Cell Therapy Trial
Chimeric Therapeutics is reporting early signs of efficacy in the world’s first clinical trial of CAR T cell therapy for neuroendocrine cancer. The first NET
NETRF Grantees Recognized for their Expertise at ENETS
Neuroendocrine cancer researchers from around the world gathered in Krakow, Poland for the 22nd Annual ENETS Conference in early March. The European Neuroendocrine Tumor Society
Advancing Neuroendocrine Tumor Research: The Urgent Need for Better Model Systems
Model systems—whether in vitro (cell lines), ex vivo (organoids), or in vivo (animal models)—are essential for understanding neuroendocrine cancer biology and testing new therapies. However,
Radiopharmaceutical ITM-11 Extends Progression-Free Survival in COMPETE Trial for GEP-NETs
The investigational therapy ITM-11 has shown promising results in the Phase 3 COMPETE trial for patients with inoperable, progressive Grade 1 and Grade 2 gastroenteropancreatic
FDA Grants Priority Review to Belzutifan as Pheo/Para Treatment
The U.S. Food and Drug Administration (FDA) has granted priority review to Merck’s application for WELIREG® (belzutifan) as a treatment for adult and pediatric patients
Advancing NET Treatment: A New Molecule for More Effective Targeted Alpha Therapy
In 2021, NETRF funded Paul Schaffer, PhD, of the University of British Columbia, for a pilot project entitled “Preclinical Toxicity and Therapy Study of 225Ac-crown-TATE.”
NETRF Awards Ten Groundbreaking Research Grants to Advance Neuroendocrine Cancer Treatment
The Neuroendocrine Tumor Research Foundation (NETRF) has announced our newest neuroendocrine cancer research grant recipients. The ten investigators receiving awards are studying the most promising
Research Reveals Potential Risks of Popular GLP-1 Medications for Some with Neuroendocrine Cancer
A team of researchers from the University of Iowa has unveiled concerns about the use of semaglutide, a widely prescribed GLP-1 receptor agonist for type
NETRF represented at NANETS 2024
NETRF was well-represented at NANETS 2024, the annual meeting of the North American Neuroendocrine Tumor Society held in November. Several hundred physicians, researchers, and patient